Cyclophosphamide
Cutaneous or Subcutaneous Lymph Node
AmgenSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Cutaneous or Subcutaneous Lymph Node cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Epirubicin Amgen | Phase 1/2 | CCC |
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Amgen | Phase 1/2 | CCC |
Pembrolizumab Amgen | Phase 1/2 | CCC |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →